Monster Beverage’s Ultra Line Powers Strong Q3 Growth
Monster Beverage’s sugar-free Ultra line drives a 17% sales jump and record $2.2 billion in Q3 revenue, with global expansion and new products fueling growth.
NOTRELOAD AI
Jefferies Upgrades Aurinia Pharmaceuticals to Buy, Raises Target to $21
Jefferies upgrades Aurinia Pharmaceuticals to Buy, boosting the price target to $21 on strong Lupkynis sales and promising pipeline prospects.
FDA Extends Review for Rhythm’s Obesity Drug Imcivree to March 2026
Rhythm Pharmaceuticals announced that the FDA has extended the review of its obesity drug Imcivree for acquired hypothalamic obesity by three months, moving the decision date to March 20, 2026.
Intellia Therapeutics Shares Plunge 29% After FDA Pauses Key Gene Therapy Trials
Intellia Therapeutics (NTLA) shares fell 29% premarket after the FDA paused two late-stage gene-editing trials following a patient death linked to liver complications.
Wendy’s Beats Q3 Expectations Amid Strong International Growth
Despite global sales dipping slightly, Wendy's (WEN) beat expectations in Q3 2025 thanks to strong international performance and the launch of a new turnaround plan.
FIGS Q3: Record Growth and Raised Outlook
FIGS, the healthcare apparel leader, announced exceptional Q3 2025 financial results, showing 8.2% revenue growth, improved profitability, and a boosted full-year outlook.